Last reviewed · How we verify
NCT06942195
Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 Diabetes
NA trial testing Ca-1000 in T2DM in 8 participants. Currently enrolling.
28 March 2026
Quick facts
| Lead sponsor | University of Adelaide |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | other |
| Enrollment | 8 |
| Start date | 22 May 2025 |
| Primary completion | 28 March 2026 |
| Estimated completion | 28 April 2026 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Ca-1000
- Ca-500
- Control
Conditions studied
- T2DM — all drugs for T2DM →
Sponsor
University of Adelaide
Who can join
Adults 18 to 70, male only, with T2DM. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The intervention in this study consists of a 75-min intraduodenal infusion of an isotonic solution containing either of calcium chloride (CaCl2) or control (saline). Participants enrolled into the study will receive, in randomised, double-blind fashion (i) Saline (control), (ii) 500 mg CaCl2, or (iii) 1000 mg CaCl2 in three separate sessions, each of which will be separated by at least 4 (and up to 10) days. Each study session will be 4-6 hours. Studies will be carried out in the Clinical Research Facility of the Adelaide Medical School, the University of Adelaide, by staff and students trained in the required techniques.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06942195
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for T2DM
Currently open trials in the same condition.
- NCT07347080 — A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) · EARLY_PHASE1 · recruiting
- NCT07005362 — Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D · recruiting
- NCT07019012 — Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients Wi · Phase 4 · recruiting
- NCT06686134 — Comprehensive Clinical Evaluation Study of GLP-1RA · recruiting
Other University of Adelaide trials
Trials by the same sponsor.
- NCT07013656 — Effects of Combined Administration of Calcium and L-tryptophan on Gut Functions and Blood Glucose in Healthy Humans · NA · not yet recruiting
- NCT06890507 — The Anti-Anginal Effects of N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Coronary Arteries (ANOCA) · Phase 2 · not yet recruiting
- NCT05682339 — Effects of Intragastric Quinine, Alone or Combined With L-isoleucine, on Postprandial Glycaemic Control · NA · completed
- NCT05769335 — Calories or Time Restriction to Alter Biomarkers of Aging and Diabetes · NA · completed
- NCT05720390 — Effects of Intragastric Quinine, Alone or Combined With L-leucine, on Postprandial Glycaemic Control · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06942195 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Adelaide
- Last refreshed: 26 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06942195.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing